Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT05433142

Public ClinicalTrials.gov record NCT05433142. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma

Study identification

NCT ID: NCT05433142
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Xencor, Inc.; Industry
Enrollment: 307 participants

Conditions and interventions

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

XmAb819 Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 12, 2022
Primary completion: Jan 31, 2027
Completion: Nov 30, 2028
Last update posted: Jun 10, 2026

2022 – 2028

United States locations

U.S. sites: 20
U.S. states: 15
U.S. cities: 18

Facility	City	State	ZIP	Site status
Xencor Investigative Site	Phoenix	Arizona	85054	Recruiting
Xencor Investigative Site	Duarte	California	91010	Recruiting
Xencor Investigative Site	Sacramento	California	95817	Recruiting
Xencor Investigative Site	New Haven	Connecticut	06520	Recruiting
Xencor Investigative Site	Jacksonville	Florida	32224	Recruiting
Xencor Investigative Site	Atlanta	Georgia	30322	Recruiting
Xencor Investigative Site	Chicago	Illinois	60611	Recruiting
Xencor Investigative Site	Chicago	Illinois	60637	Recruiting
Xencor Investigative Site	Louisville	Kentucky	40207	Recruiting
Xencor Investigative Site	Rochester	Minnesota	55905	Recruiting
Xencor Investigative Site	New Brunswick	New Jersey	088901	Recruiting
Xencor Investigative Site	New York	New York	10032	Recruiting
Xencor Investigative Site	New York	New York	10065	Recruiting
Xencor Investigative Site	Charlotte	North Carolina	28777	Recruiting
Xencor Investigative Site	Durham	North Carolina	27710	Recruiting
Xencor Investigative Site	Cincinnati	Ohio	45267	Recruiting
Xencor Investigative Site	Columbus	Ohio	43210	Recruiting
Xencor Investigative Site	Oklahoma City	Oklahoma	73104	Recruiting
Xencor Investigative Site	Nashville	Tennessee	37203	Recruiting
Xencor Investigative Site	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05433142, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 10, 2026 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05433142 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →